Krystal Biotech, Inc.
http://www.krystalbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Krystal Biotech, Inc.
Leo’s Congenital Ichthyosis Candidate Fails Phase III Study
TMB-001, a topical formulation of isotretinoin, missed its primary endpoint in the ASCEND study and will not be filed for approval. Leo is turning its attention to hand eczema and dealmaking.
Getting To Global Is A Hurdle For Cell And Gene Therapies
Only three of the 10 new therapies approved by the US FDA also have been approved in the European Union, while both of the EU gene therapy approvals followed FDA clearance, a Pink Sheet analysis shows.
US FDA May User Fee Preview: Vaccines, Gene Therapy, And Double Oncologics
Five novel agents are among the user fee goal dates coming up in May 2024.
The ‘Haves And Have-Nots’ Are Becoming Clearer In Cell And Gene Therapy
2023 saw a number of gene therapy companies go to the wall, but those that can combine clinical significance and commercial success can build sustainable businesses.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Topical Delivery
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Jeune, Inc.
- Jeune Aesthetics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice